Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Triple Negative Breast Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Neoplasm Metastasis 3 Squamous Cell Carcinoma of Head and Neck 2 Osteosarcoma 2 Lung Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Pathologic Complete Response 1 Neutropenia 1 Neoplasms 1 NSCLC 1 Myelosuppression 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Cisplatin 131 Cetuximab 80 Radiotherapy 76 Docetaxel 59 Carboplatin 46 pembrolizumab 45 Paclitaxel 44 Fluorouracil 42 Radiotherapy, Intensity-Modulated 35 Drug Therapy 17 Radiation 14 Nivolumab 14 Gefitinib 14 Gemcitabine 13 Surgical Procedures, Operative 12 Oxaliplatin 11 Erlotinib Hydrochloride 11 130-nm albumin-bound paclitaxel 11 Pemetrexed 10 Celecoxib 10 Capecitabine 10 Bevacizumab 10 tislelizumab 9 Filgrastim 9 Amifostine 9 Albumin-Bound Paclitaxel 9 durvalumab 7 atezolizumab 7 Chemoradiotherapy 7 toripalimab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Head and Neck Neoplasms × trilaciclib × Clear all

NCT06752798 2024-12-31

CCRT，LA-HNSCC

Hunan Cancer Hospital

Phase 2 Recruiting

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡